Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

7 results
Display

RE: Hepatocolic Fistula: A Potential Complication Following Radiofrequency Ablation of Liver Lesions in Patients Previously Pancreaticoduodenectomized or Cholecystectomized

Virgilio E, Orgera G, Rossi M, Ziparo V, Cavallini

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Giant Hepatic Artery Aneurysm Associated with Immunoglobulin G4-Related Disease Successfully Treated Using a Liquid Embolic Agent

Rossi M, Virgilio E, Laurino F, Orgera G, Mene P, Pirozzi N, Ziparo V, Cavallini

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A rare case of osteonecrosis of the jaw related to imatinib

Viviano M, Rossi M, Cocca S

Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erector spinae plane block in children: a narrative review

Lucente M, Ragonesi G, Sanguigni M, Sbaraglia F, Vergari A, Lamacchia R, Del Prete D, Rossi M

The erector spinae plane block (ESPB) is a novel technique used in both adult and pediatric patients. Its use in children has mostly been described in terms of perioperative pain...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pediatric Dehydration Assessment at Triage: Prospective Study on Refilling Time

Caruggi S, Rossi M, De Giacomo C, Luini C, Ruggiero N, Salvatoni , Salvatore

PURPOSE: Dehydration is a paediatric medical emergency but there is no single standard parameter to evaluate it at the emergency department. Our aim was to evaluate the reliability and validity...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Bombeccari GP, Garagiola , Pallotti F, Rossi M, Porrini M, Giannì AB, Spadari F

BACKGROUND: Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D’Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C

Background Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr